Ricardo Osorio

Array ( [id] => 16635304 [patent_doc_number] => 10913799 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Anti-RANKL antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/340290 [patent_app_country] => US [patent_app_date] => 2017-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5744 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16340290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800139 [patent_doc_number] => 20200123212 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => PEPTIDES FOR BINDING EPIDERMAL GROWTH FACTOR [patent_app_type] => utility [patent_app_number] => 16/339139 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18461503 [patent_doc_number] => 11685786 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-27 [patent_title] => Binding molecules that bind CD137 and PD-L1 [patent_app_type] => utility [patent_app_number] => 16/335971 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 58 [patent_no_of_words] => 66531 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501357 [patent_doc_number] => 20190194333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => KLRG1 DEPLETION THERAPY [patent_app_type] => utility [patent_app_number] => 16/327576 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16327576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12231947 [patent_doc_number] => 20180064810 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING' [patent_app_type] => utility [patent_app_number] => 15/701317 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 21922 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15701317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16909830 [patent_doc_number] => 11041863 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-22 [patent_title] => Frizzled-4 mutation indicator of retinopathy and intrauterine growth restriction [patent_app_type] => utility [patent_app_number] => 15/656558 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8381 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15656558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086461 [patent_doc_number] => 20190338041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/317821 [patent_app_country] => US [patent_app_date] => 2017-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12137072 [patent_doc_number] => 20180015155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-18 [patent_title] => 'COMBINATION OF PROTEIN FORMS FOR HORNFLY VACCINATION' [patent_app_type] => utility [patent_app_number] => 15/651176 [patent_app_country] => US [patent_app_date] => 2017-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9987 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15651176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14896997 [patent_doc_number] => 20190292264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => KLRG1 SIGNALING THERAPY [patent_app_type] => utility [patent_app_number] => 16/306473 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13462 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590001 [patent_doc_number] => 20180346549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => Method and Compositions for Producing Disulfide-Linked Trimeric TNF Family of Cytokines and Their Use [patent_app_type] => utility [patent_app_number] => 15/609612 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15609612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309705 [patent_doc_number] => 20190144556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/099632 [patent_app_country] => US [patent_app_date] => 2017-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -189 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16099632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585033 [patent_doc_number] => 20180086840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANTIBODIES THAT BIND TO TL1A AND THEIR USES [patent_app_type] => utility [patent_app_number] => 15/589020 [patent_app_country] => US [patent_app_date] => 2017-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15589020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743304 [patent_doc_number] => 10968279 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => TL1A antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/097630 [patent_app_country] => US [patent_app_date] => 2017-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 13 [patent_no_of_words] => 24138 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992504 [patent_doc_number] => 20170296660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'METHODS AND MATERIALS FOR MODULATING RESISTANCE TO APOPTOSIS' [patent_app_type] => utility [patent_app_number] => 15/584822 [patent_app_country] => US [patent_app_date] => 2017-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 12140 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15584822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12231944 [patent_doc_number] => 20180064808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 15/481780 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 46947 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015252 [patent_doc_number] => 11084879 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Compositions and methods for treating pancreatitis and pain with death receptor agonists [patent_app_type] => utility [patent_app_number] => 16/092142 [patent_app_country] => US [patent_app_date] => 2017-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 40 [patent_no_of_words] => 14427 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16092142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14932957 [patent_doc_number] => 20190302116 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => METHOD FOR TESTING NK CELL ACTIVITY USING SYNERGISTIC ACTIVITY OF RECEPTOR, AND METHOD FOR DIAGNOSING DISEASE ASSOCIATED WITH NK CELL ACTIVITY USING SAME [patent_app_type] => utility [patent_app_number] => 16/304103 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16304103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15882883 [patent_doc_number] => 10647774 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/436583 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 28 [patent_no_of_words] => 22775 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649196 [patent_doc_number] => 20170145096 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'METHODS FOR ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 AGENTS' [patent_app_type] => utility [patent_app_number] => 15/423325 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 28860 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15423325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11943306 [patent_doc_number] => 20170247458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR' [patent_app_type] => utility [patent_app_number] => 15/403102 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 10230 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15403102 [rel_patent_id] =>[rel_patent_doc_number] =>)